US2009156491A1PendingUtilityA1
Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit i
Assignee: CHILDREN S MEDICAL CT CORP INCPriority: Feb 16, 1996Filed: Oct 20, 2008Published: Jun 18, 2009
Est. expiryFeb 16, 2016(expired)· nominal 20-yr term from priority
C07K 14/4716A61K 38/04A61K 38/1709
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.
Claims
exact text as granted — not AI-modified1 . An isolated peptide consisting of a region of troponin subunit I having amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).
2 . A pharmaceutical composition for inhibiting angiogenesis associated with a disease or disorder in a mammal which comprises an effective amount of a peptide which is at least 80% homologous with amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).
3 . A method of inhibiting angiogenesis associated with a disease or disorder in a mammal, comprising administering an effective amount of a peptide which is at least 80% homologous with amino acid sequences selected from the group consisting of 94-123 (huTnI94-123), 104-133 (huTnI104-133), 114-143 (huTnI114-143), 129-153 (huTnI129-153), 134-173 (huTnI134-173), 144-182 (huTnI144-182), 93-112 (huTnI93-112), 98-117 (huTnI98-117), 103-122 (huTnI103-122), 108-127 (huTnI108-127), 113-132 (huTnI113-132), 118-137 (huTnI118-137), 94-113 (huTnI94-113), 98-117 (huTnI98-117), 102-121 (huTnI102-121), 106-125 (huTnI106-125), 110-129 (huTnI110-129), 114-133 (huTnI114-133), 116-123 (huTnI116-123), 118-125 (huTnI118-125), 120-127 (huTnI120-127), 122-129 (huTnI122-129), 124-131 (huTnI124-131), 126-133 (huTnI126-133), 128-135 (huTnI128-135), 130-137 (huTnI130-137), 132-139 (huTnI132-139), 134-141 (huTnI134-141), 136-143 (huTnI136-143), and 114-133 (huTnI114-133), of troponin subunit I (SEQ ID NO:17).Join the waitlist — get patent alerts
Track US2009156491A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.